Program
gilteritinib
Also written as “Gilteritinib”, “ASP2215” and “gilteritinib mini tablet”.
Its studies are mostly in Leukemia, Myeloid, Acute · Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 182 open or running | phase 3since Apr 16, 2015 | Nov 6, 2013 | Jul 31, 2028phase 2 · NCT05520567 |
| AbbVie | 10 open or running | phase 1since Aug 8, 2018 | Aug 8, 2018 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 1since Mar 26, 2020 | Mar 26, 2020 | none ahead |
Also a collaborator on its studies: Hoffmann-La Roche.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Nov 6, 2013.
- Sep 25, 2015Phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT02561455 · 9 enrolled · United States
- Oct 7, 2015Phase 1 study in Hepatic ImpairmentAstellas Pharma · NCT02571816 · 24 enrolled · United States
- Apr 22, 2016Phase 3 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT02752035 · 183 enrolled · United States, Australia, Belgium and more
- Oct 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT02927262 · 98 enrolled · United States, Brazil, Canada and more
- Dec 1, 2016Phase 3 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT02997202 · 356 enrolled · United States, Australia, Belgium and more
- Jun 8, 2017Phase 3 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT03182244 · 276 enrolled · China, Malaysia, Russia and more
- Aug 8, 2018AbbVie's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to AbbVieAbbVie · NCT03625505 · 61 enrolled · United States
- Nov 1, 2018Phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT03730012 · 11 enrolled · United States
- May 20, 2019Phase 1 study in Healthy VolunteerAstellas Pharma · NCT03964038 · 48 enrolled · United States
- Jan 21, 2020Phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT04240002 · 9 enrolled · United States, Germany, Italy and more
- Mar 26, 2020Bristol-Myers Squibb's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT04336982 · 22 enrolled · United States, Belgium, Canada and more
- Jan 6, 2021Phase 1 study in Renal ImpairedAstellas Pharma · NCT04699877 · 17 enrolled · United States, Bulgaria
- Aug 26, 2022Phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT05520567 · 70 enrolled · United States
- Aug 5, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungAstellas Pharma · NCT07140016 · 40 planned · United States, France, Spain
Ahead
- Jul 31, 2028Primary completion: phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT05520567
- Dec 31, 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungAstellas Pharma · NCT07140016
TargetBeta
“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), ”NCIt, by rule
“Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor”ChEMBL 37, by rule
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07140016Carcinoma, Non-Small-Cell Lung · United States, France, Spain | 1 | Recruiting | Astellas Pharma | Dec 31, 2029 | 40 |
| NCT05520567Leukemia, Myeloid, Acute · United States | 2 | Active, not recruiting | Astellas Pharma | Jul 31, 2028 | 70 |
| NCT04699877Renal Impaired · United States, Bulgaria | 1 | Completed | Astellas Pharma | Jul 18, 2022 | 17 |
| NCT04336982Leukemia, Myeloid, Acute · United States, Belgium, Canada and more | 1 | Terminated | Bristol-Myers Squibb | Oct 25, 2023 | 22 |
| NCT04240002Leukemia, Myeloid, Acute · United States, Germany, Italy and more | 2 | Terminated | Astellas Pharma | Mar 11, 2025 | 9 |
| NCT03964038Healthy Volunteer · United States | 1 | Completed | Astellas Pharma | Jul 2, 2019 | 48 |
| NCT03730012Leukemia, Myeloid, Acute · United States | 2 | Completed | Astellas Pharma | May 14, 2021 | 11 |
| NCT03625505Leukemia, Myeloid, Acute · United States | 1 | Completed | AbbVie | Aug 31, 2021 | 61 |
| NCT03182244Leukemia, Myeloid, Acute · China, Malaysia, Russia and more | 3 | Completed | Astellas Pharma | Dec 25, 2023 | 276 |
| NCT02997202Leukemia, Myeloid, Acute · United States, Australia, Belgium and more | 3 | Completed | Astellas Pharma | Jan 7, 2023 | 356 |
| NCT02927262Leukemia, Myeloid, Acute · United States, Brazil, Canada and more | 2 | Completed | Astellas Pharma | May 25, 2021 | 98 |
| NCT02752035Leukemia, Myeloid, Acute · United States, Australia, Belgium and more | 3 | Completed | Astellas Pharma | Mar 10, 2023 | 183 |
| NCT02571816Hepatic Impairment · United States | 1 | Completed | Astellas Pharma | Mar 5, 2016 | 24 |
| NCT02561455Leukemia, Myeloid, Acute · United States | 2 | Completed | Astellas Pharma | Jul 28, 2020 | 9 |
| NCT02456883Advanced Solid Tumors · United States | 1 | Completed | Astellas Pharma | May 20, 2017 | 6 |
| NCT02421939Leukemia, Myeloid, Acute · United States, Belgium, Canada and more | 3 | Completed | Astellas Pharma | Sep 17, 2018 | 371 |
| NCT02310321Leukemia, Myeloid, Acute · Japan, South Korea, Taiwan | 2 | Completed | Astellas Pharma | Aug 25, 2021 | 97 |
| NCT02236013Leukemia, Myeloid, Acute · United States | 1 | Completed | Astellas Pharma | Jul 26, 2021 | 80 |
| NCT02181660Leukemia, Myeloid, Acute · Japan | 1 | Completed | Astellas Pharma | Jun 27, 2016 | 24 |
| NCT02014558Leukemia, Myeloid, Acute · United States, Germany, Italy | 2 | Completed | Astellas Pharma | Aug 4, 2017 | 265 |
How it is read
Names in the registry
- “Gilteritinib”, 11 entries
- “gilteritinib”, 7 entries
- “ASP2215”, 1 entry
- “gilteritinib mini tablet”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 15 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.